Stifel Financial Corp Sells 512 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Stifel Financial Corp trimmed its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 2.3% in the third quarter, HoldingsChannel reports. The firm owned 21,571 shares of the biopharmaceutical company’s stock after selling 512 shares during the period. Stifel Financial Corp’s holdings in Xenon Pharmaceuticals were worth $849,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in shares of Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after buying an additional 1,507,135 shares during the period. Logos Global Management LP bought a new position in Xenon Pharmaceuticals in the second quarter worth approximately $14,621,000. Vestal Point Capital LP grew its stake in Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after acquiring an additional 300,000 shares during the period. Samlyn Capital LLC increased its holdings in shares of Xenon Pharmaceuticals by 61.5% during the second quarter. Samlyn Capital LLC now owns 639,685 shares of the biopharmaceutical company’s stock valued at $24,941,000 after acquiring an additional 243,489 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Xenon Pharmaceuticals by 74.7% during the second quarter. Point72 Asset Management L.P. now owns 482,022 shares of the biopharmaceutical company’s stock worth $18,794,000 after purchasing an additional 206,163 shares during the period. 95.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on XENE shares. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reissued a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Finally, Raymond James reissued an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $56.00.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 4,891 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. 5.52% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ XENE opened at $38.42 on Wednesday. The company has a market capitalization of $2.93 billion, a PE ratio of -13.62 and a beta of 1.19. The stock’s 50 day moving average price is $41.78 and its 200-day moving average price is $40.50. Xenon Pharmaceuticals Inc. has a twelve month low of $35.53 and a twelve month high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) EPS. As a group, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.